RE: EU Validation22 Jun 2021 18:43
For Dave, who needs help with reading and comprehension.
'Therefore, it is highly recommended to carry out additional validation of the clinical performance of tests for COVID-19 by comparison with a reference method in a sufficiently large number of target population subjects before
introducing the devices into the clinical routine. Scientific peer-reviewed results for the clinical validation of commercial COVID-19 tests are highly recommended before they can be safely and reliably used for medical or public health decision making. Validation refers to confirmation that the test achieves the performance levels specified by the manufacturer.
Such studies are being done by competent authorities and reference laboratories in Member States. There are obvious benefits of sharing the results of those validations and organising centralised validation studies to make the most efficient use of resources. Fast-track clinical validation studies of rapid diagnostic tests for COVID-19 by hospital laboratories are ongoing in several EU Member States. Cooperation would also be beneficial at international level where the same tests are used in different jurisdictions. Both the WHO and FIND are
currently working on validation studies of different devices.
Scarcity of reference methods and materials poses difficulties for these validation studies, and also for the evaluation of device performance by manufacturers. The Commission’s Joint Research Centre has recently developed a positive control material for RT-PCR tests which is available to laboratories in Europe. Seroconversion panels and positive sample panels are examples of further materials that are needed. Another issue currently is the lack of publicly
available comparator data, which makes it difficult to compare the performance of devices.
External quality assessment schemes could be one way to generate such data. The ECDC and the WHO are already in process of organising an external quality
assessment scheme for RT-PCR tests.
6. Actions undertaken by Commission so far
The Commission has already taken the following steps as regards market access and performance of devices:
? Facilitating continuous exchange of information between competent authorities for invitro diagnostics in the framework of the dedicated subgroup of the Medical Device Coordination Group. This includes regulatory exchanges on device conformity, availability and reliability, maintaining an inventory of devices and sharing information on national actions, covering also national derogations issued by Member States and justifications for them.
16 Note: The WHO’s emergency use assessment and listing programme (see
https://www.who.int/diagnostics_laboratory/EUL/en/) has received 30 applications and finalised'